Imaging Tracer (68Ga-FAPi-46) for Solid Tumors or Blood Cancers

This study is looking at a new imaging tracer called 68Ga-FAPi-46 to see where it goes in the body and how much it collects in normal and cancer tissues. This is done using a PET/CT scan (Positron Emission Tomography/Computed Tomography), which is a special type of imaging. You might be able to join if you are 18 or older and have certain solid tumors or blood cancers, including anal, bladder, breast, or cervical cancer. The main goal is to understand how 68Ga-FAPi-46 spreads in the body. The study plans to enroll 30 people, but its current status is unclear.

Study design
This is an interventional study with a planned enrollment of 30 participants. It is designed to evaluate the biodistribution of 68Ga-FAPi-46.
What's involved
You would receive 68Ga-FAPi-46 intravenously (into a vein) and then undergo a PET/CT scan. You may also have an optional 18F-FDG PET/CT scan.
Compensation
Not stated in the trial record.
Follow-up
The biodistribution of 68Ga-FAPi-46 will be measured for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07118176

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Active, Not Recruiting
PHASE1Ages 18+InterventionalDiagnostic
Jonsson Comprehensive Cancer Center
~30 participants
Updated 2026-07-02 on ClinicalTrials.gov
What's tested:Computed TomographyFludeoxyglucose F-18Gallium Ga 68 FAPi-46Positron Emission Tomography

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46)
Measured over Up to 2 years
Anal Carcinoma
Bladder Carcinoma
Breast Carcinoma
Cervical Carcinoma
Cholangiocarcinoma
Colorectal Carcinoma
Esophageal Carcinoma
Gastric Carcinoma
Head and Neck Carcinoma
Hematopoietic and Lymphatic System Neoplasm
Hepatocellular Carcinoma
Lung Carcinoma
Malignant Adrenal Gland Neoplasm
Malignant Brain Neoplasm
Malignant Neoplasm of Unknown Primary
Malignant Solid Neoplasm
Malignant Testicular Neoplasm
Malignant Uterine Neoplasm
Neuroendocrine Neoplasm
Ovarian Carcinoma
Pancreatic Carcinoma
Penile Carcinoma
Pleural Carcinomatosis
Primary Peritoneal Carcinoma
Prostate Carcinoma
Salivary Gland Carcinoma
Sarcoma
Skin Carcinoma
Solitary Fibrous Tumor
Thymus Carcinoma
Thyroid Gland Carcinoma
Thyroid Gland Medullary Carcinoma
Urothelial Carcinoma
Vaginal Carcinoma
1 sites across 1 states
California1
  • Jeremie Calais · PRINCIPAL_INVESTIGATOR · UCLA / Jonsson Comprehensive Cancer Center

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with the following suspected or diagnosed cancer types:
Adrenal cancer
Anal cancer
Bladder cancer
Brain cancer
Breast cancer
Cancer of unknown primary (CUP)
Cervical cancer
Cholangiocarcinoma
Colorectal cancer
Esophageal cancer
Gastric cancer
Head and neck cancer
Hematologic cancer
Hepatocellular carcinoma
Lung cancer
Medullary thyroid cancer
Neuroendocrine neoplasias
Ovarian cancer
Pancreatic cancer
Penile cancer
Peritoneal cancer
Pleural cancer
Prostate cancer
Sarcoma
Salivary gland cancer
Solitary fibrous tumor
Skin cancer
Testicular cancer
Thymus cancer
Thyroid cancer
Urothelial cancer
Uterus cancer
Vaginal cancer
Patients are ≥ 18 years old at the time of the radiotracer administration
Patient can provide written informed consent
Patient is able to remain still for duration of imaging procedure (up to one hour)

Exclusion

Patient is pregnant or nursing
Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high-quality data
  • Biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46)Up to 2 years

    Will be evaluated in normal and cancer tissues by standardized uptake values to determine where and to which degree 68Ga-FAPi-46 accumulates in normal and cancer tissues.